SCHEMBL7711330

SCHEMBL7711330

CC1Oc2ccc(C(Cc3ccc(N(C)C)cc3)NC(=O)OC(C)(C)C)cc2N=C1N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.36
CTSK P43235 2/20 0.36
ALDH1A1 P00352 7/20 0.35
NPSR1 Q6W5P4 6/20 0.35
HPGD P15428 5/20 0.35
HTT P42858 5/20 0.35
LMNA P02545 4/20 0.35
PKM P14618 3/20 0.35
HSD17B10 Q99714 3/20 0.35
TSHR P16473 3/20 0.35
TP53 P04637 2/20 0.35
MAPT P10636 2/20 0.35
AGTR1 P30556 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 5/20 0.35
MEN1 O00255 4/20 0.35
XBP1 P17861 2/20 0.35
ALOX15 P16050 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PTPRB P23467 6/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711369 0.91 ALDH1A1 (0.37) CTSSCTSKALDH1A1NPSR1HPGD
SCHEMBL7708193 0.91 ALDH1A1 (0.38) CTSSCTSKALDH1A1NPSR1HPGD
SCHEMBL7704969 0.90 ALDH1A1 (0.36) ALDH1A1NPSR1HPGDHTTLMNA
SCHEMBL7708356 0.90 CTSS (0.41) CTSSCTSKALDH1A1NPSR1HPGD
SCHEMBL7704912 0.90 ALDH1A1 (0.45) CTSSCTSKALDH1A1NPSR1HPGD
SCHEMBL7704948 0.89 SMN1; SMN2 (0.40) ALDH1A1NPSR1HPGDHTTLMNA
SCHEMBL7713438 0.87 PTPRB (0.38) ALDH1A1NPSR1HPGDHTTLMNA
SCHEMBL7710751 0.87 CA2 (0.41) ALDH1A1NPSR1HPGDHTTLMNA
SCHEMBL7708354 0.87 PPARG (0.39) ALDH1A1NPSR1HPGDHTTLMNA
SCHEMBL7711460 0.86 ALDH1A1 (0.34) ALDH1A1NPSR1HPGDHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed